Ad
related to: AstraZeneca
Search results
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks· 5 days agoFree Report) closed the most recent trading day at $78.99, moving +1.24% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.11%. Coming into today, shares of ...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 2 days agoThe Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with AstraZeneca during BIO International ...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 5 days agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth...
Democrats ramp up patent fight with drug industry in bid to lower prices
Washington Post· 10 hours agoDemocrats have hit on a new tactic in their long battle with drug companies: challenge patents that...
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 5 days agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 1 day agoIn the first quarter, Wainua royalty revenues were $1 million. Wainua generated sales of $5 million...
ASCO 2024: What's New in Breast Cancer Research?
Medscape· 2 days agoDrs Alexandra Thomas and Virginia Kaklamani discuss highlights in breast cancer research from the ASCO 2024 Annual Meeting.
Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer
MedPage Today· 6 days agoThe antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) significantly improved...
Astra’s Enhertu delays breast cancer in patients with low HER2 levels
WSAU Wausau· 5 days agoBy Deena Beasley (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to...
Germany’s Merck Bets on AI Drug-Design Partnerships, Rules Out Acquisitions – Interview
The Wall Street Journal· 14 hours agoMerck—known as EMD Group in the U.S.— is betting on artificial-intelligence partnerships to develop...